Posted by Michael Wonder on 22 Mar 2022
Ascentage Pharma's MDM2-p53 inhibitor alrizomadlin (APG-115) granted rare paediatric disease designation by the US FDA for the treatment of neuroblastoma
21 March 2022 - Ascentage Pharma today announced that its novel MDM2-p53 inhibitor, alrizomadlin (APG-115), was granted a rare paediatric disease designation by the US FDA for the treatment of neuroblastoma.
To date, alrizomadlin has received a total of six orphan drug designations and two rare paediatric disease designations by the FDA.
